Vaccine-carditis study: Spanish multicenter registry of inflammatory heart disease after COVID-19 vaccination.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pastor Pueyo Pablo, Gambó Ruberte Elena, Gayán Ordás Jara, Matute Blanco Lucía, Pascual Figal Domingo, Larrañaga Moreira José María, Gómez Barrado José Javier, González Calle David, Almenar Bonet Luis, Alonso Salinas Gonzalo Luis, Corbí Pascual Miguel José, Plaza Martín María, Pons Llinares Jaume, Durante López Alejandro, Barreiro Pérez Manuel, Candanedo Ocaña Fernando, Bautista García Javier, Merchán Ortega Germán, Domínguez Rodríguez Fernando, Martínez Mateo Virgilio, Campreciós Crespo Marta, Quintás Guzmán Martín, Jordán Martínez Laura, Aboal Viñas Jaime, Rodríguez López Judit, Fernández Santos Sara, Revilla Martí Pablo, Álvarez Roy Laura, Gómez Polo Juan Carlos, García Pinilla José Manuel, Ferré Vallverdú María, García Bueno Lourdes, Soriano Colomé Toni, Worner Diz Fernando
Аннотация
METHODS: The Vaccine-Carditis Registry has included all cases of myocarditis and pericarditis diagnosed within 30 days after COVID-19 vaccination since August 1, 2021 in 29 centers throughout the Spanish territory. The definitions of myocarditis (probable or confirmed) and pericarditis followed the consensus of the Centers for Disease Control and the Clinical Practice Guidelines of the European Society of Cardiology. A comprehensive analysis of clinical characteristics and 3-month evolution is presented.
RESULTS: From August 1, 2021, to March 10, 2022, 139 cases of myocarditis or pericarditis were recorded (81.3% male, median age 28 years). Most cases were detected in the 1st week after administration of an mRNA vaccine, the majority after the second dose. The most common presentation was mixed inflammatory disease (myocarditis and pericarditis). 11% had left ventricular systolic dysfunction, 4% had right ventricular systolic dysfunction, and 21% had pericardial effusion. In cardiac magnetic resonance studies, left ventricular inferolateral involvement was the most frequent pattern (58%). More than 90% of cases had a benign clinical course. After a 3-month follow-up, the incidence of adverse events was 12.78% (1.44% mortality).
CONCLUSIONS: In our setting, inflammatory heart disease after vaccination against SARS-CoV-2 predominantly affects young men in the 1st week after the second dose of RNA-m vaccine and presents a favorable clinical course in most cases.